Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term follow-up of bel-sar in early choroidal melanoma after AU-011-301
NL-OMON61620Phase 3Not yet recruiting
- Sponsor
- Aura Biosciences, Inc.
- Start
- Feb 2027
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of belzupacap sarotalocan in choroidal melanoma (2 arms), sponsored by Aura Biosciences, Inc. Primary endpoints: Incidence of adverse events and serious adverse events and Time to tumor progression. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
belzupacap sarotalocan
03
Conditions
choroidal melanoma
Beyond the preview
Go deeper on NL-OMON61620.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61620.